目的 观察佩索利单抗治疗泛发性脓疱型银屑病(GPP)的临床疗效.方法 应用佩索利单抗900 mg单次静脉滴注治疗1例30岁女性GPP患者,观察临床疗效及不良反应.结果 治疗1周后,患者GPP医师总体评估(GPPGA)达到2分;治疗2个月后,患者脓疱完全消失,表面只有少许鳞屑,GPP皮损面积和严重程度指数(GPPASI)评分为1,GPPGA评分为1.治疗期间患者出现类似过敏的不良反应,予得宝松肌注、抗组胺及对症治疗后好转.结论 佩索利单抗对泛发性脓疱型银屑病患者有效.
Objective To evaluate the efficacy and safety of Spesolimab in the treatment of generalized pustular psoriasis(GPP).Methods A 30 years old female with GPP was intrave-nously given 900 mg of Spesolimab once.The safety and the changes in modified generalized pus-tular psoriasis area severity index(GPPASI)and generalized pustular psoriasis physician global assessment(GPPGA)were evaluated.Results After 1 week of the treatment,the GPPGA reached 2.After 2 months of the treatment,pustules almost completely subsided and both GPPASI and GPPGA reached 1.During the treatment,the patient developed anaphylactic adverse reac-tions,which were improved following the injection of betamethasone,antihistamine and symptom-atic therapy.Conclusion Spesolimab is an effective and safe agent for the treatment of general-ized pustular psoriasis.
梁晓茜;米泽曦;许瑶函;陈永锋
南方医科大学,广东 广州 510515||南方医科大学皮肤病医院,广东 广州 510091南方医科大学皮肤病医院,广东 广州 510091
泛发性脓疱型银屑病;佩索利单抗;生物制剂;文献复习
generalized pustular psoriasis;Spesolimab;biologic agent;literature review
《皮肤性病诊疗学杂志》 2024 (005)
353-358 / 6
10.3969/j.issn.1674-8468.2024.05.010
评论